HER2-positive Metastatic Breast Cancer Clinical Trials
1 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+6 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled31 locationsNCT06625775
Recruiting
Phase 2
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
HER2-positive Metastatic Breast CancerHER2-positive Advanced Breast Cancer
Jules Bordet Institute87 enrolled1 locationNCT06595563
Recruiting
Phase 2
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
HER2-positive Metastatic Breast CancerLeptomeningeal DiseaseLeptomeningeal Metastasis
UNICANCER30 enrolled11 locationsNCT05800275
Recruiting
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
HER2-positive Metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine200 enrolled36 locationsNCT06551116
Recruiting
Not Applicable
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
Stage IV Breast CancerHER2-positive Metastatic Breast Cancer
University of Miami20 enrolled1 locationNCT05959291
Recruiting
Phase 1
PRE-I-SPY Phase I/Ib Oncology Platform Program
Metastatic Breast CancerHER2-negative Breast CancerMetastatic Cancer+5 more
QuantumLeap Healthcare Collaborative124 enrolled7 locationsNCT05868226
Recruiting
Phase 1Phase 2
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
Breast Cancer MetastaticAdvanced Breast CancerHER2-positive Metastatic Breast Cancer+1 more
Gustave Roussy, Cancer Campus, Grand Paris152 enrolled1 locationNCT06298084
Recruiting
Phase 3
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
HER2-positive Metastatic Breast CancerFirst-line Treatment
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University312 enrolled1 locationNCT06278870